NASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis $1.31 -0.05 (-3.32%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.36 +0.04 (+3.44%) As of 09/25/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ALX Oncology Stock (NASDAQ:ALXO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ALX Oncology alerts:Sign Up Key Stats Today's Range$1.29▼$1.3750-Day Range$1.31▼$2.1152-Week Range$1.05▼$2.66Volume1.17 million shsAverage Volume975,919 shsMarket Capitalization$181.15 millionP/E RatioN/ADividend YieldN/APrice Target$4.60Consensus RatingModerate Buy Company Overview ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing therapies that activate the immune system to fight cancer. The company’s approach targets the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid being identified and destroyed by macrophages and other immune cells. ALX Oncology’s lead product candidate is evorpacept, formerly known as ALX148. Evorpacept is an investigational fusion protein designed to block the CD47 “don’t eat me” signal while limiting the binding of normal blood cells. The company has evaluated evorpacept in combination with other cancer treatments, including antibody therapies, across multiple solid-tumor and hematologic cancer settings. The company’s clinical development programs have included studies in head and neck cancer, gastric and gastroesophageal-junction cancer, and other oncology indications. ALX Oncology is headquartered in South San Francisco, California, and has pursued clinical development through collaborations and trials involving research centers and patients in the United States and other regions. As a clinical-stage biotechnology company, its products remain investigational and are not approved for commercial use.AI Generated. May Contain Errors. Read More ALX Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreALXO MarketRank™: ALX Oncology scored higher than 56% of companies evaluated by MarketBeat, and ranked 444th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialALX Oncology has a consensus price target of $4.60, representing about 251.1% upside from its current price of $1.31.Amount of Analyst CoverageALX Oncology has only been the subject of 1 research reports in the past 90 days.Read more about ALX Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ALX Oncology are expected to decrease in the coming year, from ($0.59) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ALX Oncology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.18% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 7.79.Change versus previous monthShort interest in ALX Oncology has recently decreased by 11.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.11 News SentimentALX Oncology has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ALX Oncology this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,274.00 in company stock.Percentage Held by Insiders12.40% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ALX Oncology's insider trading history. Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALXO Stock News HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: ALX Oncology Holdings (ALXO), Tonix Pharma (TNXP)September 22, 2026 | theglobeandmail.comALX Oncology to Present at Upcoming Investor Conferences in SeptemberSeptember 2, 2026 | globenewswire.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 26 at 1:00 AM | Paradigm Press (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (ASTH) and ALX Oncology Holdings (ALXO)August 8, 2026 | theglobeandmail.comALX Oncology Holdings Earnings Estimates, EPS & Revenue | NASDAQ:ALXO | BenzingaJuly 7, 2026 | benzinga.comALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing RulesJune 30, 2026 | globenewswire.comALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General CounselJune 30, 2026 | globenewswire.comALX Oncology Shareholders Approve Directors and Executive PayJune 11, 2026 | tipranks.comSee More Headlines ALXO Stock Analysis - Frequently Asked Questions How have ALXO shares performed this year? ALX Oncology's stock was trading at $1.13 at the beginning of 2026. Since then, ALXO stock has increased by 15.9% and is now trading at $1.31. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. When did ALX Oncology IPO? ALX Oncology (ALXO) raised $136 million in an initial public offering on Friday, July 17th 2020. The company issued 8,500,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager. Who are ALX Oncology's major shareholders? ALX Oncology's top institutional investors include venBio Partners LLC (9.32%), BlackRock Inc. (5.50%), 5AM Venture Management LLC (2.21%) and Almitas Capital LLC (2.12%). Insiders that own company stock include Corey S Goodman, Jaume Pons, Sophia Randolph, Jason Lettmann, Peter S Garcia, Shelly Wong, Shelly Pinto and Rekha Hemrajani. View institutional ownership trends. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ALX Oncology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/06/2026Today9/26/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ALXO's financial health is in the Green zone, according to TradeSmith. ALXO has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALXO CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees48Year Founded2015Price Target and Rating Average Price Target for ALX Oncology$4.60 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+251.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$101.69 million Net MarginsN/A Pretax MarginN/A Return on Equity-90.30% Return on Assets-67.28% Debt Debt-to-Equity Ratio0.07 Current Ratio9.71 Quick Ratio9.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book2.73Miscellaneous Outstanding Shares138,280,000Free Float121,131,000Market Cap$181.15 million OptionableOptionable Beta0.39 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ALXO) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe No. 1 move you need to make before Musk’s “Starphone” goes mainstreamTech forecaster Josh Baylin, who briefed Congress on the iPhone years before its release, says Elon Musk is bu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
